|
October 2019 |
Advancing HER2+ Breast-Cancer Therapy Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) was approved by the FDA to be used in subcutaneous form for the treatment of HER2-positive breast cancer based on two large, randomized trials. The recommended dose is 600 mg/10,000 units subcutaneously over 2 to 5 minutes once every 3 weeks, with major side effects listed as fatigue, diarrhea, arthralgia, and upper respiratory tract infections. Read more. | |
Advertisement
|
|
|
First Systemic Therapy for Giant Cell Tumor Pexidartinib was approved on August 2, 2019 by the FDA as the first systematic therapy for a rare tumor type—symptomatic tenosynovial giant cell tumor. Pexidartinib showed an improvement in overall response rate in a large multicenter trial. Pexidartinib is only available through a risk-evaluation and mitigation strategy program due to liver toxicity. Read more. |
|
Pharmacogenomics Guide Oncology Treatments
Most cancer patients experience side effects from chemotherapy such as pain, depression, nausea and vomiting, neuropathy, and infections. If chemotherapy could be individualized based on genomics, healthcare practitioners might be better able to control these symptoms and choose safe and effective treatment options. Read more. |
|
|
Connect With U.S. Pharmacist
|
|
|
|
|